BioSpace News Archive

The global AI-based clinical trials solution provider market size reached USD 1.24 Billion in 2020 and is expected to register a revenue CAGR of 21.5% during the forecast period, according to latest analysis by Emergen Research

The Merck Foundation (the Foundation) announced today the launch of the Alliance for Equity in Cancer Care (the Alliance), a $20 million, five-year initiative, designed to make cancer care more equitable in the United States by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care.

The US Food and Drug Administration (FDA) has granted an Investigational Device Exemption (IDE) to Attune Medical to evaluate the company’s ensoETM in the reduction of esophageal thermal injury during cardiac radiofrequency ablation procedures.

TumorGen Inc., and PhenoVista Biosciences LLC have successfully isolated and characterized metastatic cancer cell clusters from the blood of lung cancer patients’, validating TumorGen’s novel MCCC capture technology.

The liver disease treatment market is anticipated to chart an impressive growth trajectory over the forecast period from 2020 to 2030.

miniPCR bio, a manufacturer of scientific tools for educators and researchers, today announced the launch of the Bandit™ STEM Electrophoresis Kit, an educational electrophoresis system.

The report suggests that the rise in geriatric population, which is more susceptible to thrombosis events, globally, is likely to boost the demand for thrombosis drugs during the forecast period.

Vyriad, Inc., a biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announces the appointment of Scott Beck, MBA as Chief Operating Officer.

Today, the U.S. Food and Drug Administration issued a safety communication informing patients and providers about reports of squamous cell carcinoma (SCC) and various lymphomas located in the capsule or scar tissue around breast implants.

A new study from The Leukemia & Lymphoma Society (LLS), published in Blood Cancer Discovery, a journal of the American Association for Cancer Research (https://aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-22-0077), reports that blood cancer patients who do not produce detectable antibodies after COVID-19 vaccination may have another form of protection: T-cells that are designed to attack the COVID-19 virus.